Text Size

Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis (High RIF)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Radboud University.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
European and Developing Countries Clinical Trials Partnership (EDCTP)
Sanofi-Aventis, Paris, France
Kilimanjaro Christian Medical Centre, Tanzania
Kibong'oto National Tuberculosis Hospital, Sanya Juu, Tanzania
University Centre for Chronic Diseases Dekkerswald, Groesbeek, The Netherlands
National Institute for Public Health and the Environment (RIVM)
Information provided by:
Radboud University
ClinicalTrials.gov Identifier:
NCT00760149
First received: September 25, 2008
Last updated: April 13, 2011
Last verified: March 2011
History of Changes
  Purpose

In this phase II clinical trial, the pharmacokinetics, safety and (short-term) efficacy of higher than standard doses rifampicin will be studied during the intensive phase of tuberculosis (TB) treatment. Patients enrolled in this study will either get the standard TB regimen (including 600 mg rifampicin; first study arm), or 900 mg rifampicin plus isoniazid, ethambutol and pyrazinamide in standard dosages (second study arm), or 1200 mg rifampicin plus the other drugs in standard dosages (third study arm). All patients will get the standard TB regimen during the continuation phase of treatment.


Condition Intervention Phase
Tuberculosis
 Drug: Rifampicin in higher doses
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.

Resource links provided by NLM:

MedlinePlus related topics: Tuberculosis
Drug Information available for: Rifampin
U.S. FDA Resources

Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Pharmacokinetic parameters of rifampicin, desacetylrifampicin, isoniazid, pyrazinamide, ethambutol [ Time Frame: Steady state, week 3 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Occurrence of adverse events [ Time Frame: baseline, week 1, 2, 4, 6, 8, 10, 12 ] [ Designated as safety issue: Yes ]
  • Bacteriological response of Mycobacterium tuberculosis [ Time Frame: Almost daily during first 8 weeks ] [ Designated as safety issue: No ]
  • Compare accuracy of surrogate markers (SSCC, mRNA, cytokines) with standard two-month sputum conversion marker [ Time Frame: Almost daily during first 8 weeks ] [ Designated as safety issue: No ]
  • Documenting the occurrence of mixed Mycobacterium tuberculosis strain infections [ Time Frame: Almost daily during first 8 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: July 2010
Estimated Study Completion Date: January 2012
Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
50 patients, treated with the standard anti-TB regimen, including rifampicin (600 mg), isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 2 placebo tablets resembling rifampicin 300 mg.
 Drug: Rifampicin in higher doses
Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)
Active Comparator: 2
50 patients, treated with rifampicin (900 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 1 placebo tablet resembling rifampicin 300 mg.
 Drug: Rifampicin in higher doses
Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)
Active Comparator: 3
50 patients, treated with rifampicin (1200 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment.
 Drug: Rifampicin in higher doses
Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant has a newly diagnosed pulmonary tuberculosis, confirmed by a positive smear of at least two sputum specimens with ZN staining.
  • Participant is willing to be tested for HIV.
  • Participant is at least 18, but not more than 65 years of age at the day of the first dosing of study medication.
  • Participant is admitted to KNTH or KCMC during the intensive phase of TB treatment.
  • Participant is able and willing to attend to KNTH or KCMC regularly during the continuation phase of TB treatment.
  • Participant is able to understand and willing to sign the Informed Consent Form prior to screening evaluations.
  • Female participants should understand that it is important not to get pregnant during the study. They should agree on taking measures to prevent them from getting pregnant during the study. They should agree on taking measures to prevent them from getting pregnant, such as using a contraceptive device or barrier method.

Exclusion Criteria:

  • Participant has been treated with anti-tuberculosis drugs during the past three years.
  • Participant's body weight is less than 50 kg.
  • Participant has abnormal liver function test or serum creatinine (defined as levels higher than the upper limit of normal).
  • Participant has a relevant medical history or current condition that might interfere with drug absorption, distribution, metabolism or excretion (i.e. chronic gastro-intestinal disease, Diabetes Mellitus, renal or hepatic disease, use of concomitant drugs that interfere with the pharmacokinetics of anti-TB drugs).
  • Participant is on anti-retroviral treatment at inclusion.
  • Participant has a CD4 count less than 350 cells/mm3.
  • Participant has a Karnofsky score of less than 40.
  • Participant is pregnant or breastfeeding.
  • Participant has a Multi Drug Resistant (MDR)-TB for which another than the standard treatment regimen is needed.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00760149

Contacts
Contact: Gibson Kibiki, MD, MMed, PhD +255 754 572767 gkibiki@gmail.com
Contact: Georgette Plemper van Balen, PhD +31 24 8186776 G.PlemperVanBalen@ulc.umcn.nl

Locations
Tanzania
Kibong'oto National Tuberculosis Hospital Recruiting
Sanya Juu, Kilimanjaro, Tanzania, P.O. box 12
Contact: Liberate Mleoh, MD     +255 27 2756194     lmleoh@yahoo.com    
Contact: Riziki Kisonga, MD     +255 755 659206     kisonga2002@yahoo.com    
Sub-Investigator: Liberate Mleoh, MD            
Sub-Investigator: Jossy van den Boogaard, MD            
Sub-Investigator: Charles Mtabho, MD, MPH            
Sub-Investigator: Hadija Semvua, Pharm-B, MPH            
Sub-Investigator: Cecile Magis-Escurra, MD            
Sub-Investigator: Elton Kisanga, Pharm-B, PhD            
Sub-Investigator: Martin Boeree, MD, PhD            
Sub-Investigator: Dick van Soolingen, MSc, PhD            
Sub-Investigator: Andre van der Ven, MD, PhD            
Sub-Investigator: Wil Dolmans, MD PhD            
Sponsors and Collaborators
Radboud University
European and Developing Countries Clinical Trials Partnership (EDCTP)
Sanofi-Aventis, Paris, France
Kilimanjaro Christian Medical Centre, Tanzania
Kibong'oto National Tuberculosis Hospital, Sanya Juu, Tanzania
University Centre for Chronic Diseases Dekkerswald, Groesbeek, The Netherlands
National Institute for Public Health and the Environment (RIVM)
Investigators
Principal Investigator: Rob Aarnoutse, Pharm-D, PhD Radboud University
Principal Investigator: Gibson Kibiki, MD, MMed, PhD Kilimanjaro Christian Medical Centre, Moshi, Tanzania
Principal Investigator: Martin Boeree, MD PhD Radboud University Nijmegen Medical Center/UCCZ Dekkerswald
  More Information

Publications:

Responsible Party: Rob Aarnoutse, PharmD, PhD, Radboud University Nijmegen Medical Centre, the Netherlands
ClinicalTrials.gov Identifier: NCT00760149     History of Changes
Other Study ID Numbers: APRIORI 4.1, PACTR2009060001493909
Study First Received: September 25, 2008
Last Updated: April 13, 2011
Health Authority: Tazania: Tanzanian Food and Drug Administration

Keywords provided by Radboud University:
tuberculosis
rifampicin
pharmacokinetics
pharmacodynamics

Additional relevant MeSH terms:
Tuberculosis
Tuberculosis, Pulmonary
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Rifampin
 Antibiotics, Antitubercular
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antitubercular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on May 22, 2013